Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.36 |
| ▸ | CKS1B | P61024 | 2/20 | 0.33 |
| ▸ | SKP1 | P63208 | 2/20 | 0.33 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SCD | O00767 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.30 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5498909 | 0.88 | LPAR1 (0.35) | ACSS2CKS1BSKP1SKP2CNR2 | |
| SCHEMBL5500498 | 0.81 | NPFFR1 (0.36) | ACSS2CKS1BSKP1SKP2MEN1 | |
| SCHEMBL5497926 | 0.80 | TLR7 (0.38) | ACSS2CKS1BSKP1SKP2ALDH1A1 | |
| SCHEMBL5493523 | 0.80 | MAPKAPK2 (0.32) | ACSS2MEN1KMT2AALDH1A1MAPKAPK2 | |
| SCHEMBL5526455 | 0.77 | BRD9 (0.35) | ACSS2CNR2MEN1KMT2ABRD9 | |
| SCHEMBL5147587 | 0.75 | CKS1B (0.38) | ACSS2CKS1BSKP1SKP2MEN1 | |
| SCHEMBL3109532 | 0.74 | HDAC4 (0.35) | MEN1KMT2AALDH1A1 | |
| SCHEMBL3109524 | 0.74 | HDAC4 (0.35) | MEN1KMT2AALDH1A1 | |
| SCHEMBL27620912 | 0.74 | MEN1 (0.34) | MEN1KMT2ALMNAALDH1A1MAPK1 | |
| SCHEMBL3122762 | 0.74 | SIRT5 (0.38) | MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556389-B9 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2015-09-09 | — | — | EP | disclosed |
| EP-1556389-B3 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2015-04-01 | — | — | EP | disclosed |
| EP-1556389-B1 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2007-07-25 | — | — | EP | disclosed |
| US-20070037786-A1 | Cephem compounds | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| US-7129232-B2 | For therapy of of infectious diseases | ASTELLAS PHARMA INC. (JP) | 2006-10-31 | — | — | US | disclosed |
| US-20040132994-A1 | Cephem compounds | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037786-A1 | Cephem compounds | CEP170, ABCB11, SLC7A1 | ACSS2 1009/4885CKS1B 2311/4885SKP1 768/4885 |
| US-20040132994-A1 | Cephem compounds | CEP170, ABCB11, RCC2 | ACSS2 1294/4885CKS1B 2415/4885SKP1 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.